Skip to main content
Top
Published in: Breast Cancer Research 3/2006

01-06-2006 | Review

What can be learnt from models of incidence rates?

Authors: Graham A Colditz, Bernard A Rosner

Published in: Breast Cancer Research | Issue 3/2006

Login to get access

Abstract

Models of breast cancer incidence have evolved from the observation by Armitage and Doll in the 1950s that the pattern of incidence by age differs for reproductive cancers from those of other major malignancies. Both two-stage and multistage models have been applied to breast cancer incidence. Consistent across modeling approaches, risk accumulation or the rate of increase in breast cancer incidence is most rapid from menarche to first birth. Models that account for the change in risk after menopause and the temporal sequence of reproductive events summarize risk efficiently and give added insights to potentially important mechanistic features. First pregnancy has an adverse impact on progesterone receptor negative tumors, while increasing parity reduces the risk of estrogen/progesterone receptor positive tumors but not estrogen/progesterone receptor negative tumors. Integrated prediction models that incorporate prediction of carrier status for highly penetrant genes and also account for lifestyle factors, mammographic density, and endogenous hormone levels remain to be efficiently implemented. Models that both inform and reflect the emerging understanding of the molecular and cell biology of carcinogenesis are still a long way off.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kaldor J, Day N: Mathematical models in cancer epidemiology. Cancer Epidemiology. Edited by: Schottenfeld D, Fraumeni J. 1996, New York:Oxford University Press, 127-137. Kaldor J, Day N: Mathematical models in cancer epidemiology. Cancer Epidemiology. Edited by: Schottenfeld D, Fraumeni J. 1996, New York:Oxford University Press, 127-137.
3.
6.
go back to reference Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM: Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005, 97: 715-723.CrossRefPubMed Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM: Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005, 97: 715-723.CrossRefPubMed
7.
go back to reference Doll R, Peto R: Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Comm Health. 1978, 32: 303-313.CrossRef Doll R, Peto R: Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Comm Health. 1978, 32: 303-313.CrossRef
8.
go back to reference Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 1988, 319: 525-532.CrossRefPubMed Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 1988, 319: 525-532.CrossRefPubMed
9.
go back to reference Brown C, Chu K: Use of multistage models to infer stage affectedby carcinogenic exposure: example of lung cancer and cigarette smoking. J Chron Dis. 1987, 40 (Suppl 2): 171s-179s.CrossRefPubMed Brown C, Chu K: Use of multistage models to infer stage affectedby carcinogenic exposure: example of lung cancer and cigarette smoking. J Chron Dis. 1987, 40 (Suppl 2): 171s-179s.CrossRefPubMed
10.
go back to reference Hazelton W, Clements M, Moolgavkar S: Multistage carcinogenesis and ling cancer mortality in three cohorts. Cancer Epidemiol Bio Prevention. 2005, 14: 1171-1181. 10.1158/1055-9965.EPI-04-0756.CrossRef Hazelton W, Clements M, Moolgavkar S: Multistage carcinogenesis and ling cancer mortality in three cohorts. Cancer Epidemiol Bio Prevention. 2005, 14: 1171-1181. 10.1158/1055-9965.EPI-04-0756.CrossRef
11.
go back to reference Little M, Hawkins M, Charles M, Hildreth N: Fitting the Armitage-Doll model to radiation-exposed cohorts and implications for population cancer risks. Radiation Research. 1992, 132: 207-221.CrossRefPubMed Little M, Hawkins M, Charles M, Hildreth N: Fitting the Armitage-Doll model to radiation-exposed cohorts and implications for population cancer risks. Radiation Research. 1992, 132: 207-221.CrossRefPubMed
12.
13.
go back to reference Fisher B, Costantino J, Wickerham D, Redmond C, Kavanah M, Cronin W, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed Fisher B, Costantino J, Wickerham D, Redmond C, Kavanah M, Cronin W, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed
14.
go back to reference Moolgavkar SH, Day NE, Stevens RG: Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J Natl Cancer Inst. 1980, 65: 559-569.PubMed Moolgavkar SH, Day NE, Stevens RG: Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J Natl Cancer Inst. 1980, 65: 559-569.PubMed
15.
go back to reference Moolgavkar S, Knudson A: Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst. 1981, 66: 1037-1052.CrossRefPubMed Moolgavkar S, Knudson A: Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst. 1981, 66: 1037-1052.CrossRefPubMed
16.
go back to reference Pathak DR, Whittemore AS: Combined effects of body size, parity, and menstrual events on breast cancer incidence in seven countries. Am J Epidemiol. 1992, 135: 153-168.CrossRefPubMed Pathak DR, Whittemore AS: Combined effects of body size, parity, and menstrual events on breast cancer incidence in seven countries. Am J Epidemiol. 1992, 135: 153-168.CrossRefPubMed
17.
go back to reference Pike MC, Kolonel LN, Henderson BE, Wilkens LR, Hankin JH, Feigelson HS, Wan PC, Stram DO, Nomura AM: Breast cancer in a multiethnic cohortin Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 2002, 11: 795-800.PubMed Pike MC, Kolonel LN, Henderson BE, Wilkens LR, Hankin JH, Feigelson HS, Wan PC, Stram DO, Nomura AM: Breast cancer in a multiethnic cohortin Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 2002, 11: 795-800.PubMed
18.
go back to reference Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG: "Hormonal" risk factors, "breast tissue age" and the age-incidence of breast cancer. Nature. 1983, 303: 767-770. 10.1038/303767a0.CrossRefPubMed Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG: "Hormonal" risk factors, "breast tissue age" and the age-incidence of breast cancer. Nature. 1983, 303: 767-770. 10.1038/303767a0.CrossRefPubMed
19.
go back to reference Rosner B, Colditz GA, Willett WC: Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 1994, 139: 819-835.CrossRefPubMed Rosner B, Colditz GA, Willett WC: Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 1994, 139: 819-835.CrossRefPubMed
20.
go back to reference Rosner B, Colditz G: Nurses' health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst. 1996, 88: 359-364.CrossRefPubMed Rosner B, Colditz G: Nurses' health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst. 1996, 88: 359-364.CrossRefPubMed
22.
go back to reference Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ: Biology of disease: comparison study of human and rat mammary tumorigenesis. Lab Invest. 1990, 62: 244-278.PubMed Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ: Biology of disease: comparison study of human and rat mammary tumorigenesis. Lab Invest. 1990, 62: 244-278.PubMed
24.
go back to reference Trichopoulos D, Hsieh C, MacMahon B, Lin T, Lowe C, Mirra A: Age at any birth and breast cancer risk. Int J Cancer. 1983, 31: 701-704.CrossRefPubMed Trichopoulos D, Hsieh C, MacMahon B, Lin T, Lowe C, Mirra A: Age at any birth and breast cancer risk. Int J Cancer. 1983, 31: 701-704.CrossRefPubMed
25.
go back to reference Janerich DT, Hoff MB: Evidence for a crossover in breast cancerrisk factors. Am J Epidemiol. 1982, 116: 737-742.CrossRefPubMed Janerich DT, Hoff MB: Evidence for a crossover in breast cancerrisk factors. Am J Epidemiol. 1982, 116: 737-742.CrossRefPubMed
26.
go back to reference Lilienfeld AM: The relationship of cancer of the female breast to artificial menopause and marital status. Cancer. 1956, 9: 927-934.CrossRefPubMed Lilienfeld AM: The relationship of cancer of the female breast to artificial menopause and marital status. Cancer. 1956, 9: 927-934.CrossRefPubMed
27.
go back to reference Trichopoulos D, MacMahon B, Cole P: Menopause and breast cancerrisk. J Natl Cancer Inst. 1972, 48: 605-613.PubMed Trichopoulos D, MacMahon B, Cole P: Menopause and breast cancerrisk. J Natl Cancer Inst. 1972, 48: 605-613.PubMed
28.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy. Combined reanalysis of data from 51 epidemiological studies involving 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997, 350: 1047-1059. 10.1016/S0140-6736(97)08233-0.CrossRef Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy. Combined reanalysis of data from 51 epidemiological studies involving 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997, 350: 1047-1059. 10.1016/S0140-6736(97)08233-0.CrossRef
29.
go back to reference Pike M, Ross R, Spicer D: Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol. 1998, 147: 718-721.CrossRefPubMed Pike M, Ross R, Spicer D: Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol. 1998, 147: 718-721.CrossRefPubMed
30.
go back to reference Rockhill B, Colditz G, Rosner B: Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol. 2000, 151: 404-408.CrossRefPubMed Rockhill B, Colditz G, Rosner B: Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol. 2000, 151: 404-408.CrossRefPubMed
31.
go back to reference Colditz G, Rosner B: Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000, 152: 950-964. 10.1093/aje/152.10.950.CrossRefPubMed Colditz G, Rosner B: Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000, 152: 950-964. 10.1093/aje/152.10.950.CrossRefPubMed
32.
go back to reference Colditz G, Frazier A: Models of breast cancer show that risk isset by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev. 1995, 4: 567-571.PubMed Colditz G, Frazier A: Models of breast cancer show that risk isset by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev. 1995, 4: 567-571.PubMed
33.
go back to reference Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005, 353: 1784-1792. 10.1056/NEJMoa050518.CrossRefPubMed Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005, 353: 1784-1792. 10.1056/NEJMoa050518.CrossRefPubMed
34.
go back to reference Colditz G, Rosner B, Chen WY, Holmes M, Hankinson SE: Risk factors for breast cancer:according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004, 96: 218-228.CrossRefPubMed Colditz G, Rosner B, Chen WY, Holmes M, Hankinson SE: Risk factors for breast cancer:according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004, 96: 218-228.CrossRefPubMed
35.
go back to reference Yasui Y, Potter J: The shape of the age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control. 1999, 10: 431-437. 10.1023/A:1008970121595.CrossRefPubMed Yasui Y, Potter J: The shape of the age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control. 1999, 10: 431-437. 10.1023/A:1008970121595.CrossRefPubMed
36.
go back to reference Tarone R, Chu K: The greater impact of menopause on ER-than ER+breast cancer incidence: a possible explanation (United States). Cancer Causes Control. 2002, 13: 7-14. 10.1023/A:1013960609008.CrossRefPubMed Tarone R, Chu K: The greater impact of menopause on ER-than ER+breast cancer incidence: a possible explanation (United States). Cancer Causes Control. 2002, 13: 7-14. 10.1023/A:1013960609008.CrossRefPubMed
37.
go back to reference Hulka BS, Chambless L, Wilkinson W, Deubner D, McCarty KS, McCarty KJ: Hormonal and personal effects of estrogen receptors in breast cancer. Am J Epidemiol. 1984, 119: 692-704.CrossRefPubMed Hulka BS, Chambless L, Wilkinson W, Deubner D, McCarty KS, McCarty KJ: Hormonal and personal effects of estrogen receptors in breast cancer. Am J Epidemiol. 1984, 119: 692-704.CrossRefPubMed
38.
go back to reference Hildreth NG, Kelsey , Eisenfeld AJ, LiVolsi VA, Holford TR, Fischer DB: Differences in breast cancer risk factors according to the estrogenreceptor level of the tumor. J Natl Cancer Inst. 1983, 70: 1027-1031.PubMed Hildreth NG, Kelsey , Eisenfeld AJ, LiVolsi VA, Holford TR, Fischer DB: Differences in breast cancer risk factors according to the estrogenreceptor level of the tumor. J Natl Cancer Inst. 1983, 70: 1027-1031.PubMed
39.
go back to reference Nomura A, Tashiro H, Hamada Y, Shigematsu T: Relationship between estrogen receptors and risk factors of breast cancer in Japanese pre- and postmenopausal patients. Breast Cancer Res Treat. 1994, 4: 37-43. 10.1007/BF01806986.CrossRef Nomura A, Tashiro H, Hamada Y, Shigematsu T: Relationship between estrogen receptors and risk factors of breast cancer in Japanese pre- and postmenopausal patients. Breast Cancer Res Treat. 1994, 4: 37-43. 10.1007/BF01806986.CrossRef
40.
go back to reference Hislop TG, Coldman AJ, Elwood JM, Skippen DH, Kan L: Relationship between risk factors for breast cancer and hormonal status. Int J Epidemiol. 1986, 15: 469-476.CrossRefPubMed Hislop TG, Coldman AJ, Elwood JM, Skippen DH, Kan L: Relationship between risk factors for breast cancer and hormonal status. Int J Epidemiol. 1986, 15: 469-476.CrossRefPubMed
41.
go back to reference McTiernan A, Thomas DB, Johnson LK, Roseman D: Risk factors forestrogen receptor-rich and estrogen receptor-poor breast cancers. J Natl Cancer Inst. 1986, 77: 849-854.PubMed McTiernan A, Thomas DB, Johnson LK, Roseman D: Risk factors forestrogen receptor-rich and estrogen receptor-poor breast cancers. J Natl Cancer Inst. 1986, 77: 849-854.PubMed
42.
go back to reference Stanford JL, Szklo M, Boring CC, Brinton LA, Diamond EA, Greenberg RS, Hoover RN: A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol. 1987, 125: 184-194.CrossRefPubMed Stanford JL, Szklo M, Boring CC, Brinton LA, Diamond EA, Greenberg RS, Hoover RN: A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol. 1987, 125: 184-194.CrossRefPubMed
43.
go back to reference Cooper JA, Rohan TE, Cant EL, Horsfall DJ, Tilley WD: Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study. Br J Cancer. 1989, 59: 119-125.CrossRefPubMedPubMedCentral Cooper JA, Rohan TE, Cant EL, Horsfall DJ, Tilley WD: Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study. Br J Cancer. 1989, 59: 119-125.CrossRefPubMedPubMedCentral
44.
go back to reference Kreiger N, King WD, Rosenberg L, Clarke EA, Palmer JR, Shapiro S: Steroid receptor status and the epidemiology of breast cancer. Ann Epidemiol. 1991, 1: 513-523.CrossRefPubMed Kreiger N, King WD, Rosenberg L, Clarke EA, Palmer JR, Shapiro S: Steroid receptor status and the epidemiology of breast cancer. Ann Epidemiol. 1991, 1: 513-523.CrossRefPubMed
45.
46.
go back to reference Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR: Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?. Cancer Epidemiol Biomarkers Prev. 1995, 4: 319-326.PubMed Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR: Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?. Cancer Epidemiol Biomarkers Prev. 1995, 4: 319-326.PubMed
47.
go back to reference Yoo KY, Tajima K, Miura S, Takeuchi T, Hirose K, Risch H, Dubrow R: Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. Am J Epidemiol. 1997, 146: 307-314.CrossRefPubMed Yoo KY, Tajima K, Miura S, Takeuchi T, Hirose K, Risch H, Dubrow R: Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. Am J Epidemiol. 1997, 146: 307-314.CrossRefPubMed
48.
go back to reference Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000, 151: 703-714.CrossRefPubMed Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000, 151: 703-714.CrossRefPubMed
49.
go back to reference Rich SS, Sellers TA: Genetic epidemiologic methods. The Genetic Basis of Common Diseases. Edited by: King RA, Motulsky AG. 2002, New York, NY: Oxford University Press, Inc, 39-49. Rich SS, Sellers TA: Genetic epidemiologic methods. The Genetic Basis of Common Diseases. Edited by: King RA, Motulsky AG. 2002, New York, NY: Oxford University Press, Inc, 39-49.
50.
go back to reference Jacobsen O: Heredity in Breast Cancer. 1946, London: HK Lewis Jacobsen O: Heredity in Breast Cancer. 1946, London: HK Lewis
51.
go back to reference Anderson VE, Goodman HO, Reed SC: Variables Related to Human Breast Cancer. 1958, Minneapolis: University of Minnesota Press Anderson VE, Goodman HO, Reed SC: Variables Related to Human Breast Cancer. 1958, Minneapolis: University of Minnesota Press
52.
go back to reference Claus EB, Risch NJ, Thompson WD: Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol. 1990, 131: 961-972.CrossRefPubMed Claus EB, Risch NJ, Thompson WD: Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol. 1990, 131: 961-972.CrossRefPubMed
53.
go back to reference Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991, 48: 232-242.PubMedPubMedCentral Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991, 48: 232-242.PubMedPubMedCentral
54.
go back to reference Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990, 250: 1684-1689.CrossRefPubMed Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990, 250: 1684-1689.CrossRefPubMed
55.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed
56.
go back to reference Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998, 62: 145-58. 10.1086/301670.CrossRefPubMedPubMedCentral Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998, 62: 145-58. 10.1086/301670.CrossRefPubMedPubMedCentral
57.
go back to reference Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004, 23: 1111-1130. 10.1002/sim.1668.CrossRefPubMed Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004, 23: 1111-1130. 10.1002/sim.1668.CrossRefPubMed
59.
go back to reference Ottman R, Pike MC, King MC, Henderson BE: Practical guide for estimating risk for familial breast cancer. Lancet. 1983, 2: 556-558. 10.1016/S0140-6736(83)90580-9.CrossRefPubMed Ottman R, Pike MC, King MC, Henderson BE: Practical guide for estimating risk for familial breast cancer. Lancet. 1983, 2: 556-558. 10.1016/S0140-6736(83)90580-9.CrossRefPubMed
60.
go back to reference Claus EB, Risch N, Thompson WD: The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 1993, 28: 115-120. 10.1007/BF00666424.CrossRefPubMed Claus EB, Risch N, Thompson WD: The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 1993, 28: 115-120. 10.1007/BF00666424.CrossRefPubMed
61.
go back to reference Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002, 20: 2701-2712. 10.1200/JCO.2002.05.121.CrossRefPubMed Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002, 20: 2701-2712. 10.1200/JCO.2002.05.121.CrossRefPubMed
62.
go back to reference Rockhill B, Byrne C, Rosner B, Louie MM, Colditz G: Breast cancer risk prediction with a log-incidence model: evaluation of accuracy. J Clin Epidemiol. 2003, 56: 856-861. 10.1016/S0895-4356(03)00124-0.CrossRefPubMed Rockhill B, Byrne C, Rosner B, Louie MM, Colditz G: Breast cancer risk prediction with a log-incidence model: evaluation of accuracy. J Clin Epidemiol. 2003, 56: 856-861. 10.1016/S0895-4356(03)00124-0.CrossRefPubMed
63.
go back to reference Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment forpreventing breast cancer. J Natl Cancer Inst. 1999, 91: 1829-1846. 10.1093/jnci/91.21.1829.CrossRefPubMed Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment forpreventing breast cancer. J Natl Cancer Inst. 1999, 91: 1829-1846. 10.1093/jnci/91.21.1829.CrossRefPubMed
64.
go back to reference Tice JA, Cummings SR, Ziv E, Kerlikowske K: Mammographic breastdensity and the Gail model for breast cancer risk prediction in a screeningpopulation. Breast Cancer Res Treat. 2005, 94: 115-122. 10.1007/s10549-005-5152-4.CrossRefPubMed Tice JA, Cummings SR, Ziv E, Kerlikowske K: Mammographic breastdensity and the Gail model for breast cancer risk prediction in a screeningpopulation. Breast Cancer Res Treat. 2005, 94: 115-122. 10.1007/s10549-005-5152-4.CrossRefPubMed
65.
go back to reference Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Willett WC, Rosner B, Colditz GA: Early life factors and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev. 2005, 14: 2889-2897. 10.1158/1055-9965.EPI-05-0525.CrossRefPubMed Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Willett WC, Rosner B, Colditz GA: Early life factors and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev. 2005, 14: 2889-2897. 10.1158/1055-9965.EPI-05-0525.CrossRefPubMed
66.
go back to reference Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Cho E, Willett WC, Colditz GA: Adolescent diet and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev. 2003, 12: 1159-1167.PubMed Baer HJ, Schnitt SJ, Connolly JL, Byrne C, Cho E, Willett WC, Colditz GA: Adolescent diet and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev. 2003, 12: 1159-1167.PubMed
Metadata
Title
What can be learnt from models of incidence rates?
Authors
Graham A Colditz
Bernard A Rosner
Publication date
01-06-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1414

Other articles of this Issue 3/2006

Breast Cancer Research 3/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine